Glenmark Pharmaceuticals Shares

• 

  Glenmark Life Sciences IPO Subscribed Nearly 45 Times On Final Day Of Issue

  Glenmark Life Sciences' share sale via initial public offering (IPO) was subscribed by 44.17 times on Thursday, July 29- the third and final day of its issue.

• 

  Glenmark Life Sciences IPO Opens Today

  Glenmark Life Sciences IPO, which will be open for three days until July 29, will consist of a fresh issue of Rs 1,060 crore and an offer for sale of up to 6.30 million shares

• 

  Glenmark Life Sciences IPO To Open Tomorrow. Should You Subscribe?

  Glenmark Life Sciences' IPO will consist of a fresh issue of Rs 1,060 crore and an offer for sale of up to 6.30 million shares by Glenmark Pharmaceuticals

• 

  Glenmark Life Sciences IPO To Open On July 27. Here's All You Need To Know

  Glenmark Life Sciences' IPO will consist of a fresh issue of Rs 1,060 crore and an offer for sale of up to 6.30 million shares by Glenmark Pharmaceuticals

• 

  Glenmark Arm Files Papers For Rs 1,160 Crore Glenmark Life Sciences' IPO

  The IPO comprises a fresh issue of up to Rs 1,160 crore and an offer for sale of up to 73.05 lakh equity shares by Glenmark Pharmaceuticals.

• 

  Glenmark Life Sciences Files IPO Papers With Sebi

  Glenmark Life Sciences IPO: The offer will comprise a fresh issue of up to Rs 1,160 crore and an offer for sale of up to 73,05,245 equity shares of Rs 2 each of Glenmark Life Sciences by Glenmark Pharmaceuticals

• 

  Glenmark Defends Price Of Its COVID-19 Drug Favipiravir Version

  Glenmark denied making any claims that "favipiravir alone" is effective in treatment of mild-to-moderate COVID-19 patients.

• 

  Glenmark To Conduct Clinical Trials For Potential COVID-19 Drug; Shares Surge

  Glemark said the approval made it the first pharmaceutical company in India to be given the go-ahead to start trials on COVID-19 patients.

• 

  Glenmark Pharma To Conduct Trials For Potential COVID-19 Drug, Shares Jump

  Glenmark Pharmaceuticals, which rose as much as 8.9 per cent to Rs 359, traded up 5.9 per cent at 9:37 am.

• 

  Glenmark Pharma Receives 7 Observations From US Regulator On Baddi Unit, Shares Fall

  Glenmark Pharmaceuticals said the Baddi unit contributes approximately 10 per cent of the revenue of US sales.

• 

  Glenmark Gets US Regulator's Nod For Leukemia Treatment Drug

  The company's current portfolio consists of 112 products authorised for distribution in the US marketplace and 63 ANDA pending approval with the US regulator.

• 

  Glenmark Pharma Shares Gain Over 4% Post Q2 Results

  Glenmark's consolidated revenue was up 16.48 per cent to Rs 2,224.10 crore during the quarter under review as against Rs 1,909.36 in the same period last year.

• 

  Glenmark Pharma Q2 Profit Rises 3% To Rs 223 Crore

  The pharmaceuticals company had reported a net profit of Rs 216.10 crore for the corresponding period of the previous fiscal year.

• 

  Glenmark Pharma Gets USFDA Nod For Anti-Fungal Ointment

  Glenmark Pharmaceuticals today said it has received final approval from the US health regulator for anti-fungal ointment nystatin and triamcinolone acetonide.

• 

  Buy Aurobindo Pharma, Lupin; Short State Bank of India: Ruchit Jain

  Markets staged a good rally in trades on Thursday wherein Nifty broke above its crucial psychological level of 8,850 after consolidating in the previous two sessions. Ruchit Jain, equity technical analyst with Angel Broking, shared his trading strategies on a few stocks.